1. Home /
  2. Biotechnology

Biotechnology

A Pair of Rare Disease Biotech Concerns Worth a Good Look

A Pair of Rare Disease Biotech Concerns Worth a Good Look

Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.

Retrophin Tanks After Neurological Treatment Fails Late-Stage Study

Retrophin Tanks After Neurological Treatment Fails Late-Stage Study

The treatment, fosmetpantotenate, fails to meet its primary endpoint when compared to a control group being treated with a placebo, the company says.

Teva Rises on Positive Test Results for Migraine Treatment

Teva Rises on Positive Test Results for Migraine Treatment

Teva says patients taking Ajovy experienced a significant reduction in migraine days compared to those receiving placebos.

Here's Why I Like These 2 High Risk/High Reward Small Caps

Here's Why I Like These 2 High Risk/High Reward Small Caps

I dub Resonant and Chiasma as 'busted IPOs'.

Sarepta Craters After FDA Rejection of Muscular Dystrophy Drug

Sarepta Craters After FDA Rejection of Muscular Dystrophy Drug

In its rejection of golodirsen, Sarepta's second treatment for Duchenne muscular dystrophy, the FDA cites concerns over infection risk 'related to intravenous infusion ports and renal toxicity,' the company says.

Teva's Generic EpiPen Jr Is Now Available for $300

Teva's Generic EpiPen Jr Is Now Available for $300

There has been an EpiPen shortage in the U.S., Europe and Canada, thanks to manufacturing delays at Pfizer.

Endo, Allergan Nearing Deals to Limit Ohio Litigation Over Opioids - Report

Endo, Allergan Nearing Deals to Limit Ohio Litigation Over Opioids - Report

Allergan is said to be discussing paying $5 million while Endo is close to an agreement to pay $10 million, according to a report.

5 Favorites for Biotech Stock Buyers

5 Favorites for Biotech Stock Buyers

For those with a long-term horizon, here are some top picks.

Amarin Shares Show Heart as Anti-Cholesterol Drug Firm Bucks Market Rout

Amarin Shares Show Heart as Anti-Cholesterol Drug Firm Bucks Market Rout

Amarin's stock jumped after SVB Leerink upped its rating on the biotech's stock to outperform, saying a recent double-digit decline offers a buying opportunity.

Deciphera Soars on Positive Phase III Drug Trial

Deciphera Soars on Positive Phase III Drug Trial

Deciphera Pharma stock more than doubled on positive results from a Phase III clinical study of its drug to treat patients with advanced gastrointestinal stromal tumors.